Colloidal Bismuth in the Treatment of Duodenal Ulceration: The Benefit for the Patient

References

• Tytgat G NJ, Nio C Y. Mucosa protectives: sucralfate and colloidal bismuth subcitrate in peptic ulcer disease. Z Gastroenterol 1987; 25(suppl 3)152–161
   Google Scholar
• Wagstaff A J, Benfield P, Monk J P. Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs 1988; 36: 132–157
   PubMed Web of Science ®Google Scholar
• McLsaac R L, McCanless I, Summers K, Wood J R. Ranitidine and cimetidine in the healing of duodenal ulcer: meta-analysis of comparative clinical trials. Aliment Pharmacol Ther 1987; 1: 369–381
   Google Scholar
• Hall D W. Review of the modes of action of colloidal òismuth subcitrate. Scand J Gastroenterol 1989; 24(suppl 157)3–6
   Google Scholar
• Miller J P, Faragher E B. Relapse of duodenal ulcer: ! does it matter which drug is used in initial treatment?. Br Med J 1986; 293: 1117–1118
   PubMed Web of Science ®Google Scholar
• Boyd E JS, Penston J G, Johnston P A, Wormsley K G. Does maintenance therapy keep duodenal ulcers healed?. Lancet 1988; 1: 1324–1327
   PubMed Web of Science ®Google Scholar
• Bardhan K D. Intermittent treatment of duodenal ulcer with cimetidine. Br Med J 1980; 281: 20–22
   PubMedGoogle Scholar
• Gudmand-Hoyer E, Jensen K B, Krag E, et al. 1 Prophylactic effect of cimetidine in duodenal ulcer disease. Br Med J 1978; 1: 1095–1097
   PubMed Web of Science ®Google Scholar
• Korman M G, Hetzel D J, Hansky J, Shearman D JC, Don G. Relapse rate of duodenal ulcer after cessation of long-term cimetidine treatment. Dig Dis Sci 1980; 25: 88–91
   PubMed Web of Science ®Google Scholar
• Boyd E JS, Wormsley K G. Natural history of duodenal ulcer. Surv Dig Dis 1985; 3: 230–239
   Google Scholar
• Gough K R, Korman M G, Bardhan K D, et al. Ranitidine and cimetidine in prevention of duodenal ulcer relapse. Lancet 1984; 2: 659–662
   PubMed Web of Science ®Google Scholar
• Silvis S E. Final report on the United States multi-center trial comparing ranitidine to cimetidine as maintenance therapy following healing of duodenal ulcer. J Clin Gastroenterol 1985; 7: 482–487
   PubMed Web of Science ®Google Scholar
• Martin D F, Hollanders D, May S J, et al. Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate. Lancet 1981; 1: 7–10
   PubMed Web of Science ®Google Scholar
• Moshal M G, Spitaels M D. The superiority of initial treatment with ulcerone (De-Nol) on the endoscopic rate of relapse of duodenal ulcers. Proceedings of 6th World Congress of Gastroenterology, Madrid, 1978
   Google Scholar
• Kang J Y, Piper D W. Cimetidine and colloidal bismuth in treatment of chronic duodenal ulcer. Digestion 1982; 23: 73–79
   PubMed Web of Science ®Google Scholar
• Shreeve D R, Klass H J, Jones P E. Comparison of cimetidine and tripotassium dicitrato bismuthate in healing and relapse of duodenal ulcers. Digestion 1983; 28: 96–101
   PubMed Web of Science ®Google Scholar
• Bianchi Porro G, Barbara L, Cheli R, Dal Monte P R, Mazzaca G. Comparison of tripotassium dicitrato bismuthate (TDB) tablets and ranitidine in the healing and relapse of duodenal ulcers. Gut 1984; 25: A565
   Google Scholar
• Lee F I, Samloff T M, Hardman M. Comparison of tri-potassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. Lancet 1985; 1: 1299–1302
   PubMed Web of Science ®Google Scholar
• Hamilton I, O'Connor H J, Wood N C, Bradbury I, Axon A TR. Healing and recurrence of duodenal ulcer after treatment with tripotassium dictrato bismuthate (TDB) tablets or cimetidine. Gut 1986; 27: 106–110
   PubMed Web of Science ®Google Scholar
• Coghlan J G, Gilligan D, Humphries H, et al. Campylobacter pylori and recurrence of duodenal ulcers–a 12 month follow-up study. Lancet 1987; 2: 1109–1111
   PubMed Web of Science ®Google Scholar
• Smith A C, Price A B, Borrielo P, Levi A J. A comparison of ranitidine and tripotassium dicitrato-bismuth (TDB) in relapse rates of duodenal ulcer. The role of Campylobacter pylori. Gastroenterology 1988; 94: A431
   Web of Science ®Google Scholar
• McLean A J, Harrison P M, Loannides-Demos L, Byrne A J, McCarthy P, Dudley F J. The choice of ulcer healing agent influences duodenal ulcer relapse rate and long-term clinical outcome. Aust NZ J Med 1985; 15: 367–374
   PubMedGoogle Scholar
• Dobrilla G, Vallaperta P, Amplatz S. Influence of ulcer healing agents on ulcer relapse after discontinuation of acute treatment: a pooled estimate of controlled clinical trials. Gut 1988; 29: 181–187
   PubMed Web of Science ®Google Scholar
• Lam S K, Hui W M, Lau W Y, et al. Sucralfate overcomes adverse effect of cigarette smoking on duodenal ulcer healing and prolongs subsequent remission. Gastroenterology 1987; 92: 1193–1201
   PubMed Web of Science ®Google Scholar
• Marks I N, Wright J P, Lucke W, Girdwood A H. Relapse rates following initial ulcer healing with sucralfate and cimetidine. Scand J Gastroenterol 1983; 18(suppl 83)53–56
   Google Scholar
• Solhaug J H, Carling L, Glise H, et al. Ulcer recurrences following initial ulcer healing with sucralfate or cimetidine. Scand J Gastroenterol 1987; 22(suppl 127)77–80
   Google Scholar
• Lane M R, Lee S P. Recurrence of duodenal ulcer after medical treatment. Lancet 1988; 1: 1147–1149
   PubMed Web of Science ®Google Scholar
• Berstad A. Antacids in the treatment of gas-troduodenal ulcer. Scand J Gastroenterol 1986; 21: 385–391
   PubMed Web of Science ®Google Scholar
• Bardhan K D, Hunter J O, Miller J P, et al. Antacid maintenance therapy in the prevention of duodenal ulcer relapse. Gut 1988; 29: 1748–1754
   PubMed Web of Science ®Google Scholar
• Mohammed R, Holden R J, Hearns J B, McKibben B M, Buchanan K D, Crean G P. Effects of eight weeks' continuous treatment with oral ranitidine and cimetidine on gastric acid secretion, pepsin secretion and fasting serum gastrin. Gut 1983; 24: 61–66
   PubMed Web of Science ®Google Scholar
• Frislid K, Aadland E, Berstad A. Augmented postprandial gastric acid secretion due to exposure to ranitidine in healthy subjects. Scand J Gastroenterol 1986; 21: 119–122
   PubMed Web of Science ®Google Scholar
• Gavey C J, Szeto M-L, Nwokolo C, Pounder R E. Does oral tripotassium dicitrate bismuthate (TDB) provide a depot preparation of bismuth?. Gut 1988; 29: A1495
   Google Scholar
• Wyatt J I, Dixon M F. Chronic gastritis–a pathogenetic approach. J Pathol 1988; 154: 113–124
   PubMed Web of Science ®Google Scholar
• Wyatt J I. The role of Campylobacter pylori in the pathogenesis of peptic ulcer disease. Scand J Gastroenterol 1989; 24(suppl 157)7–11
   Web of Science ®Google Scholar
• Wyatt J I, Rathbone B J, Dixon M F, Heatley R V. Campylobacter pyloridis and acid induced gastric metaplasia in the pathogenesis of duodenitis. J Clin Pathol 1987; 40: 841–848
   PubMed Web of Science ®Google Scholar
• Jones D M, Eldridge J, Whorwell P J, Miller J P. The effects of various anti-ulcer regimens and antibiotics on the presence of Campylobacter pyloridis and its antibody. Campylobacter III, A D Pearson, M B Skirrow, H Lior, B Rowe. Public Health Laboratory Service, London 1985
   Google Scholar
• Misiewicz J J. What is new in the epidemiology and pathogenesis of peptic ulcer?. Aliment Pharmacol Ther 1987; 1: 510S–517S
   Google Scholar
• McNulty C AM. The treatment of Campylobacter-associated gastritis. Am J Gastroenterol 1987; 82: 245–247
   PubMed Web of Science ®Google Scholar
• Marshall B J, Armstrong J A, Francis G J, Nokes N T, Wee S H. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion 1987; 37(suppl 2)16–30
   PubMed Web of Science ®Google Scholar
• Rauws E AJ, Langenberg W, Houthoff H J, Zanen H C, Tytgat G NJ. Campylobacter-pyloridis-associated chronic active antral gastritis. Gastroenterology 1988; 94: 33–40
   PubMedGoogle Scholar
• Borody T, Cole P, Noonan S, et al. Long-term Campylobacter pylori recurrence post-eradication. Gastroenterology 1988; 94: A43
   Web of Science ®Google Scholar